Evidence map›Paper›PMID 35387856›Full record

Observational studyNeurology2022

Multimodal Quality of Life Assessment in Post-9/11 Veterans With Epilepsy: Impact of Drug Resistance, Traumatic Brain Injury, and Comorbidity.

James J Gugger, Eamonn Kennedy, Samin Panahi, David F Tate, Ali Roghani, Anne C Van Cott, M Raquel Lopez, Hamada Altalib, Ramon Diaz-Arrastia, Mary Jo Pugh

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

James J GuggerFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0003-1113-2984
Eamonn KennedyFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0002-9211-1271
Samin PanahiFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.
David F TateFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0003-0213-1920
Ali RoghaniFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0003-4309-592X
Anne C Van CottFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.
M Raquel LopezFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0003-2421-5682
Hamada AltalibFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.
Ramon Diaz-ArrastiaFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.
Mary Jo PughFrom the Department of Neurology (J.J.G., R.D.-A.), University of Pennsylvania, Philadelphia; University of Utah (E.K., S.P., D.F.T., A.R., M.J.P.), Salt Lake City, UT; University of Pittsburgh (A.C.V.C.), PA; University of Miami (M.R.L.), FL; and Yale University (H.A.), New Haven, CT.ORCID 0000-0003-4196-7763
University of Utah · US

Funding

Training Program in Neuroengineering and MedicineT32NS091006 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Brian Litt · 2015 to 2026
$4.1M
NINDS NIH HHS T32 NS091006
6 · The paper itself

Abstract

BACKGROUND AND

objectivesEpilepsy is defined by the occurrence of multiple unprovoked seizures, but quality of life (QOL) in people with epilepsy is determined by multiple factors, in which psychiatric comorbid conditions play a pivotal role. Therefore, understanding the interplay between comorbid conditions and QOL across epilepsy phenotypes is an important step toward improved outcomes. Here, we report the impact of QOL across distinct epilepsy phenotypes in a cohort of post-9/11 veterans with high rates of traumatic brain injury (TBI).

methodsThis observational cohort study from the Veterans Health Administration included post-9/11 veterans with epilepsy. A process integrating an epilepsy identification algorithm, chart abstraction, and self-reported measures was used to classify patients into 1 of 4 groups: (1) epilepsy controlled with medications, (2) drug-resistant epilepsy (DRE), (3) posttraumatic epilepsy (PTE), or (4) drug-resistant PTE (PT-DRE). Summary scores for 6 QOL measures were compared across the groups after adjustment for age, sex, and number of comorbid conditions.

resultsA total of 529 survey respondents with epilepsy were included in the analysis: 249 controls (i.e., epilepsy without DRE or PTE), 124 with DRE, 86 with PTE, and 70 with PT-DRE. DRE was more common in those with PTE compared with those with nontraumatic epilepsy (45% vs 33%, odds ratio 1.6 [95% CI 1.1-2.4], DISCUSSION: Among those with PTE, DRE prevalence was significantly higher than prevalence of nontraumatic epilepsies. PTE was also associated with higher burden of comorbidity and worse overall QOL compared to nontraumatic epilepsies. People with PTE are distinctly vulnerable to the comorbid conditions associated with TBI and epilepsy. This at-risk group should be the focus of future studies aimed at elucidating the factors associated with adverse health outcomes and developing antiepileptogenic therapies.

Indexed as

Brain Injuries, TraumaticDrug Resistant EpilepsyEpilepsyEpilepsy, Post-TraumaticVeteransComorbidityDrug ResistanceHumansQuality of Life

Identifiers

PMID35387856
PMCPMC9071370
OpenAlexW4224950770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.